Tyra Biosciences

TYRA · NASDAQ

$20.47+$1.13 (+5.84%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $19.34

TYRA analyst rating

BuyConsensus of 13 analysts over the last 12 months. 92% rate it a buy.

Strong buy0
Buy12
Hold1
Underperform0
Sell0

12-month price target · 13 analysts

Average $48.40 (+136.5% upside)

Low: $29.29
Now: $20.47
High: $61.95

Upgrades and downgrades

The latest rating actions, newest first

TYRA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Oppenheimer	Sep 22, 2026	Maintains	Outperform	$50.00 → $40.00	17%
HC Wainwright & Co.	Sep 22, 2026	Maintains	Buy	$30.00 → $29.00	32%
Wedbush	Sep 10, 2026	Maintains	Outperform	$53.00	39%
HC Wainwright & Co.	Sep 10, 2026	Maintains	Buy	$45.00 → $30.00	32%
HC Wainwright & Co.	Sep 4, 2026	Maintains	Buy	$45.00	32%
Jones Trading	Jun 17, 2026	Initiates	Buy	$56.00	0%
B of A Securities	Jun 10, 2026	Maintains	Buy	$37.00 → $42.00	60%
Wolfe Research	May 19, 2026	Initiates	Peer Perform	—	37%
HC Wainwright & Co.	May 14, 2026	Maintains	Buy	$45.00	32%
Guggenheim	Apr 15, 2026	Initiates	Buy	$54.00	46%

The case for and against

Updated Oct 14, 2026

Bull case

Tyra Biosciences is supported by a differentiated precision-medicine platform in SNAP and a pipeline of three clinical-stage FGFR small molecules aimed at overcoming the toxicity and resistance limits of first-generation pan-FGFR inhibitors. The cited data reinforce a positive therapeutic-index thesis: 60mg dabogratinib showed 0/22 Grade 3 treatment-related adverse events, no discontinuations or dose reductions, and no clinically significant hyperphosphatemia, nail, or ocular toxicity, while BEACH301 has cleared five sentinel doses without a reported safety signal. That clean safety profile matters because Tyra’s key value drivers are chronic, prolonged-use settings in pediatric ACH and other FGFR-driven diseases, where tolerability, durability, and selectivity can translate into meaningful clinical and commercial differentiation.

Bear case

Tyra Biosciences is a high-risk clinical-stage biotech whose valuation depends almost entirely on dabogratinib and TYRA-200, with relatively low assumed probabilities of approval of 20%, 40%, 40%, and 35% under an 11% discount rate and 2% terminal growth rate. The bearish view is driven by unresolved execution risk in urothelial carcinoma, where efficacy must continue to mature as the cohort expands toward 30 patients, and where the company itself flags concerns about inconsistent dose-level efficacy, durability, and safety-related dose modifications. The reliance on a narrow pipeline, a potentially longer or more onerous registrational path, and possible medium- to long-term dilution risk further weaken the fundamental case.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.